ABSTRACT OBJECTIVES This study aimed to determine whether remote ischemic conditioning (RIC) initiated prior to primary percutaneous coronary intervention (PPCI) could reduce myocardial infarct (MI) size in patients presenting with ST-segment elevation myocardial infarction.
D espite optimal myocardial reperfusion using primary percutaneous coronary intervention (PPCI), the morbidity and mortality of ST-segment elevation myocardial infarction (STEMI) patients remains substantial. One neglected therapeutic target, in these patients, is myocardial reperfusion injury, which describes myocardial injury and cell death that results, paradoxically, from reperfusing an acutely ischemic myocardium, and which contributes up to 50% of the final myocardial infarct (MI) size (1) . Novel therapeutic interventions are required to protect the heart against myocardial reperfusion injury in order to reduce MI size, preserve left ventricular (LV) systolic function, and improve clinical outcomes in this patient group (2) .
Remote ischemic conditioning (RIC) has emerged as a novel therapeutic intervention for protecting the heart against acute ischemia-reperfusion injury. RIC describes the endogenous cardioprotective effect elicited by applying $1 brief nonlethal cycle of ischemia and reperfusion to an organ or tissue remote from the heart (3, 4) . In the clinical setting, this can be implemented by inflating a blood pressure cuff placed on the upper arm or thigh to induce the RIC stimulus in the arm or leg (5) . This noninvasive, low-cost, therapeutic intervention has been reported to be beneficial in patients undergoing coronary artery bypass graft surgery (6, 7) , and elective percutaneous coronary intervention (PCI) (8) . More recently, RIC has been investigated in STEMI patients treated by PPCI (9, 10) .
Cardiac magnetic resonance (CMR) has emerged as the imaging modality of choice to assess the cardioprotective efficacy of novel therapeutic interventions in PPCI-treated STEMI patients. CMR accurately and reproducibly measures MI size (11) , but more importantly, can also measure the myocardial salvage index (MSI) (12) . MSI is a sensitive measure of cardioprotective efficacy, representing the proportion of the myocardium at risk of infarction "rescued" by a therapeutic intervention-this requires that the myocardium or area at risk (AAR) be quantified. The current CMR method for in vivo AAR estimation is to use T 2 -weighted CMR imaging 2 to 7 days following PPCI to delineate the extent of myocardial edema (13) (14) (15) . Recent studies of novel cardioprotective interventions have used MSI to demonstrate efficacy without reduction in absolute infarct size (16, 17) , but it has also been reported that the therapeutic intervention may itself reduce the extent of infarct-related myocardial edema (18) , thereby precluding its use for calculating MSI.
Whether RIC can reduce MI size and, potentially, myocardial edema is unknown. In the current study, EXPERIMENTAL PROTOCOL. In order to protect the heart against myocardial reperfusion injury, the therapeutic intervention has to be initiated prior to myocardial reperfusion. As such, patients were randomly assigned to either RIC or control protocols on arrival in hospital, and the allocated treatment was initiated prior to PPCI. A computer-generated randomization sequence was used. Sequentially numbered, sealed envelopes were opened after consent had been obtained, and these contained the study group assignment. Randomization, treatment allocation, and delivery of RIC were all performed by an unblinded investigator who was not involved with data collection or analysis. The PPCI operator, catheter laboratory and coronary care unit staff, the investigator collecting and analyzing the data, and the investigators analyzing the coronary angiograms and CMR scans were all blinded to the treatment allocation.
In patients randomized to the RIC treatment arm, a ing to microvascular obstruction AE intramyocardial hemorrhage; and 2) the remote myocardium, as previously described (18) , to obtain mean T 2 values. Our methodology differed slightly from that by Thuny et al. (18) in that the whole of the AAR, and remote myocardium, was sampled (5 slice estimates per subject).
Furthermore, the derivation of a signal intensity ratio was not required as absolute T 2 values are provided by the map. (23) 29 (30) 27 (27) Medically treated diabetes 5 (13) 1 (2) 9 (9) 4 (4)
Family history of CAD 6 (15) 10 (23) 15 (15) 20 (20) Pre-infarct angina 4 (10) 5 (12) 11 (11) 
RESULTS
A total of 363 patients with suspected STEMI were screened for study eligibility. Of these, 323 patients were randomized to receive either RIC or control protocols on immediate arrival at the PPCI center and proceeded to coronary angiography to confirm the diagnosis of STEMI and to exclude patients with pre-PPCI TIMI flow grade >0 (Figure 1 ): 1) 164 of these patients were randomized to the control group, of whom 98 patients were eligible for perprotocol analysis, with 84 patients being included in the analysis for hsTnT levels, and of those 84 patients, 40 patients were analyzed for CMR outcomes; 2) 159 of these patients were randomized to the RIC group, of whom 99 patients were eligible for the per-protocol analysis, with 89 patients finally being analyzed for hsTnT levels, and of those 89 patients, 43 patients were analyzed for CMR outcomes. There were no major differences in the baseline patient characteristics and treatments between the 2 study arms (Tables 1 and 2 ). In the majority of patients, the RIC or control protocols overlapped with the beginning of the PPCI procedure, and blinding of the PPCI operator was maintained as the protocol was continued underneath the sterile drapes. There were no reported adverse outcomes with RIC. Representative CMR images from 3 different study patients are shown in Figure 2 .
R I C r e d u c e d M I s i z e i n S T E M I p a t i e n t s .
Compared with the control patients, STEMI patients who were administered RIC prior to PPCI had a reduction in MI size (measured by CMR and expressed as a percent of the LV) of 27% (p ¼ 0.009) ( Figure 3A) . Furthermore, we found that the RIC, when compared with the control group, protocol reduced absolute MI mass (p ¼ 0.029) ( Table 3) .
Finally, the RIC, when compared with the control group, protocol also significantly reduced plasma levels of hsTnT at 24 h (p ¼ 0.037) ( Figure 3B , Table 3 ) and resulted in a nonsignificant reduction in total 24-h AUC hsTnT (p ¼ 0.09) ( Figure 3B , Table 3 ).
In a multivariable analysis adjusting for the effects of baseline variables (age, sex, body mass index, smoking, hypertension, dyslipidemia, diabetes, family history of coronary artery disease, pre-infarct angina, ischemia time, BARI score, APPROACH score) 
R I C i m p r o v e d m y o c a r d i a l s a l v a g e i n S T E M I
p a t i e n t s . Because RIC was found to reduce the extent of myocardial edema, this precluded its use as a measure of the AAR and its validity to calculate MSI. However, using CMR-independent angiographic jeopardy scores (BARI and APPROACH) to estimate the AAR (Table 2) , we found that the MSI was increased by >50% with the RIC, when compared with the control, protocol (p ¼ 0.03) ( Table 3) . The actual mechanism through which RIC protects the myocardium from acute ischemia-reperfusion White et al.
currently remains unclear, although it has been suggested that a neurohormonal pathway conveys the cardioprotective signal from the remotely conditioned arm to the heart (4). The current paradigm suggests that an as yet unidentified humoral factor produced in response to the remote conditioning stimulus, which then conveys the protective signal to the heart, where known cardioprotective pathways are then activated (4). Interestingly, it appears that an intact neural pathway to the limb is required for the production of the humoral factor (31, 32) . Whatever the putative mechanism, RIC has been previously reported to protect the heart against acute ischemia- in that study (10) . Furthermore, although follow-up of this cohort seemed to suggest long-term benefit, the primary composite endpoint of major adverse cardiac and cerebrovascular event was driven by noncardiac mortality (35) .
The reason for the positive effect of RIC in our study in terms of MI size reduction may relate to a number of factors: 1) we delivered the standard RIC protocol on arrival at the PPCI center; 2) we only selected STEMI patients with complete occlusion in the infarct-related artery (pre-PPCI TIMI flow grade 0), as these patients were less likely to have spontaneously reperfused and therefore most likely to benefit from RIC; and 3) we used CMR to measure the MI size reduction, which would be expected to be more sensitive than either serum cardiac enzymes and/or single-photon emission computed tomography analysis (36) .
The ability to assess the cardioprotective efficacy of a novel therapeutic intervention in STEMI patients treated by PPCI, can be optimized by measuring MSI.
The MSI offers a more sensitive measure of cardioprotective efficacy in cases where absolute MI size reduction is not detectable between the therapeutic intervention and control, because it "normalizes" for the differences in the AAR that exist between STEMI patients. T 2 -weighted CMR is a histologically validated, noninvasive, imaging technique for retrospectively measuring the AAR (13-15), but it has evoked controversy, and traditional sequences (e.g., black-blood STIR) are recognized to have limitations (37, 38) . Newer sequences have improved on this (39, 40) . We chose to use T 2 -mapping CMR in this study for the following reasons: there is evidence to support that it is more robust when compared with traditional STIR imaging (21) ; it has recently been histologically validated (41) ; and it provides a data output map that is quantitative.
We found that RIC not only reduced the extent of myocardial edema, but it also lowered T 2 values within the AAR. Similarly, Thuny et al. (18) found that ischemic post-conditioning, another "mechanical"
therapeutic intervention for reducing myocardial This suggests that whether the therapeutic intervention affects myocardial edema may be specific to the therapy under investigation. Further work is needed to better understand the pathophysiology of myocardial edema in the setting of a reperfused MI.
STUDY LIMITATIONS. A large number of patients were randomized but were not included in the final CMR analysis (Figure 1) . The main reasons for this included: 1) patient randomization took place prior to coronary angiography, before a definitive diagnosis of STEMI could be confirmed; and 2) a proportion of randomized patients had pre-PCI TIMI flow grade >0 and were thus excluded. Despite achieving a significant reduction in the primary study endpoint, we found only a trend to reduction in hsTnT. We believe that the study was underpowered for this secondary endpoint and recruitment was designed to detect MI size by a more sensitive method (CMR). This has also been seen in similar, yet positive studies (10) . 
CONCLUSIONS

